HC Wainwright Issues Negative Outlook for DAWN Earnings

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) - Stock analysts at HC Wainwright lowered their Q2 2025 earnings estimates for Day One Biopharmaceuticals in a report issued on Wednesday, May 7th. HC Wainwright analyst A. Maldonado now anticipates that the company will earn ($0.32) per share for the quarter, down from their prior forecast of ($0.30). HC Wainwright currently has a "Buy" rating and a $36.00 price objective on the stock. The consensus estimate for Day One Biopharmaceuticals' current full-year earnings is ($0.72) per share. HC Wainwright also issued estimates for Day One Biopharmaceuticals' Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.28) EPS, FY2025 earnings at ($1.25) EPS, FY2026 earnings at ($0.34) EPS and FY2027 earnings at $0.58 EPS.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($0.35) earnings per share for the quarter, topping analysts' consensus estimates of ($0.46) by $0.11. The company had revenue of $30.76 million for the quarter, compared to the consensus estimate of $30.28 million.

Other equities analysts have also issued research reports about the stock. Wedbush restated an "outperform" rating and set a $25.00 target price on shares of Day One Biopharmaceuticals in a research report on Wednesday, May 7th. The Goldman Sachs Group dropped their target price on shares of Day One Biopharmaceuticals from $39.00 to $27.00 and set a "buy" rating for the company in a research report on Tuesday, March 25th. JPMorgan Chase & Co. lowered their price objective on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an "overweight" rating for the company in a research report on Wednesday, March 5th. Finally, Needham & Company LLC lowered their price objective on shares of Day One Biopharmaceuticals from $30.00 to $27.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of $30.57.

Day One Biopharmaceuticals Trading Up 2.0%

Shares of NASDAQ:DAWN traded up $0.13 during midday trading on Friday, reaching $6.58. 1,293,810 shares of the company were exchanged, compared to its average volume of 1,079,747. The business's fifty day moving average is $7.64 and its two-hundred day moving average is $11.00. Day One Biopharmaceuticals has a one year low of $6.26 and a one year high of $17.14. The stock has a market cap of $666.96 million, a PE ratio of -6.39 and a beta of -1.24.

Institutional Trading of Day One Biopharmaceuticals

A number of institutional investors have recently modified their holdings of the company. FMR LLC boosted its holdings in shares of Day One Biopharmaceuticals by 73.9% in the 4th quarter. FMR LLC now owns 12,887,467 shares of the company's stock valued at $163,284,000 after buying an additional 5,475,087 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Day One Biopharmaceuticals by 1.6% in the 1st quarter. Vanguard Group Inc. now owns 5,943,243 shares of the company's stock valued at $47,130,000 after buying an additional 94,320 shares in the last quarter. Franklin Resources Inc. boosted its holdings in shares of Day One Biopharmaceuticals by 0.3% in the 4th quarter. Franklin Resources Inc. now owns 3,882,952 shares of the company's stock valued at $49,197,000 after buying an additional 13,320 shares in the last quarter. Estuary Capital Management LP boosted its holdings in shares of Day One Biopharmaceuticals by 35.5% in the 4th quarter. Estuary Capital Management LP now owns 3,716,777 shares of the company's stock valued at $47,092,000 after buying an additional 972,997 shares in the last quarter. Finally, Pictet Asset Management Holding SA boosted its holdings in shares of Day One Biopharmaceuticals by 17.0% in the 4th quarter. Pictet Asset Management Holding SA now owns 3,490,064 shares of the company's stock valued at $44,219,000 after buying an additional 507,398 shares in the last quarter. 87.95% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Day One Biopharmaceuticals news, CEO Jeremy Bender sold 12,048 shares of the firm's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $144,094.08. Following the transaction, the chief executive officer now owns 128,015 shares of the company's stock, valued at approximately $1,531,059.40. This trade represents a 8.60% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, General Counsel Adam Dubow sold 4,646 shares of the firm's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $55,566.16. Following the transaction, the general counsel now directly owns 39,602 shares in the company, valued at $473,639.92. This trade represents a 10.50% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 21,064 shares of company stock valued at $251,925 in the last 90 days. Company insiders own 6.20% of the company's stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.